← All 4d Molecular Therapeutics, INC filings

4d Molecular Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
FDMT
4d Molecular Therapeutics, INC
10-K: 4DMT Advances Gene Therapies, Secures Otsuka Deal Amidst Pipeline Prioritization
4D Molecular Therapeutics reports significant progress in its gene therapy pipeline, including positive clinical data for 4D-150 and 4D-710, and a major collaboration with Otsuka Pharmaceutical, while navigating substantial net losses and a strategic workforce reduction.
NASDAQ
FDMT
4d Molecular Therapeutics, INC
10-K: 4D Molecular Therapeutics Reports 2024 Results, Highlights Progress in Wet AMD and Cystic Fibrosis Programs
4D Molecular Therapeutics' 10-K filing details the company's financial results for 2024 and provides updates on its key clinical programs, including 4D-150 for wet AMD and DME and 4D-710 for cystic fibrosis.
NASDAQ
FDMT
4d Molecular Therapeutics, INC
10-K: 4D Molecular Therapeutics Bolsters Leadership and Outlines Pipeline Progress in New Filings
4D Molecular Therapeutics details a new executive appointment, compensation agreements, and provides updates on its clinical and preclinical programs in recent SEC filings.